Lanreotide supply disruption may extend beyond H1 FY27
Pharmathen's manufacturing pause and 483 observations could delay resupply, impacting U.S. revenue.
CIPLA / Q3-FY26 / risks
Keep the risk register visible.
Cipla · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
U.S. launch pipeline may face delays or competition
Respiratory and peptide launches are critical to offset Lenalidomide decline; any delay or increased competition could pressure revenue.
Elevated R&D spend may persist, pressuring margins
R&D at 7% of revenue is above historical 5-6% range; management expects normalization but lumpy spending could continue.
Semaglutide generic launch could impact tirzepatide uptake
Analyst questioned whether Cipla's agreement with Lilly restricts entry into semaglutide; management was evasive.